Novartis

X @novartis

⚔ Compare ☆ Follow Own this channel?

🔄 Data last refreshed 18 hours ago

🤝

Make a deal with Novartis

🔒 Paid proposals held safely in escrow — released only when the work's approved.

Followers

287.2K

Posts

13.3K

Following

513

Account age

17 yrs

🎁 Free analysisfor Novartis

🕵️Fake Followers CheckReal-audience % & bot risk→ 📊Engagement rateBenchmarked vs. peers→ 💰What they chargeFair sponsored-post price→

Known for

#Investors: Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

Press release: https://t.co/LsQDK889sL
IR Webcast: https://t.co/2ZdKCI1G2z

#NVSQ425

5.8K views #Investors: Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025 Press release: https://t.co/LsQDK889sL IR Webcast: https://t.co/2ZdKCI1G2z #NVSQ425

#Investors:
Novartis delivered strong growth in priority brands and recent launches during Q1 2026, while US generic erosion weighed on results as expected. We remain on track to deliver our full year guidance.

Press release: https://t.co/c3x8o96Gsf
IR Webcast:

4.2K views #Investors: Novartis delivered strong growth in priority brands and recent launches during Q1 2026, while US generic erosion weighed on results as expected. We remain on track to deliver our full year guidance. Press release: https://t.co/c3x8o96Gsf IR Webcast:

Novartis delivered a strong Q2 25 with double-digit sales growth and core margin expansion. We advanced our pipeline, and key launches are accelerating. We upgraded our FY 25 core operating income guidance and remain confident in our mid- to long-term growth outlook.

4.2K views Novartis delivered a strong Q2 25 with double-digit sales growth and core margin expansion. We advanced our pipeline, and key launches are accelerating. We upgraded our FY 25 core operating income guidance and remain confident in our mid- to long-term growth outlook.

In Q3 2025, Novartis delivered solid sales and core operating income growth with strong pipeline progress.

Our key growth drivers performed well, and we had important innovation milestone achievements including an FDA approval and positive data readout that has the potential to

4K views In Q3 2025, Novartis delivered solid sales and core operating income growth with strong pipeline progress. Our key growth drivers performed well, and we had important innovation milestone achievements including an FDA approval and positive data readout that has the potential to

📊 Post performance

3.4K

Avg views / post

1.2%

Reach vs followers

Nov 2008

On X since

🔥 Top post: #News: @US_FDA approval of our new oral, targeted therapy for #C · 5.8K views

📊 Activity & format

Posting cadence

0.3 / week

A lower-frequency account — each post lands with more weight.

Content mix

Mostly video

Recent: 8 video · 4 image · 4 text.

Follower / following

560×

Follows 513 back. A strong ratio — an audience that follows them, not a follow-for-follow network.

Recent posts

View on X ↗

🔥 Top post #News: @US_FDA approval of our new oral, targeted therapy for #ChronicSpontaneousUrticaria brings new hope for patients and underlines our commitment to making bold progress in immunology. 🔗 5.8K❤ 22🔁 19

#NVSQ226 Novartis social media posts on Q2 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NV… 4K❤ 7🔁 2

On Tuesday, July 21, Novartis will announce its Q2 2026 results. Register to listen here: https://t.co/LIilPfqDRK #NovartisNews $NVS $NOVN #NVSQ226 2.1K❤ 8🔁 1

▶ #Investors: Novartis delivered strong growth in priority brands and recent launches during Q1 2026, while US generic erosion weighed on results as expected. We remain on track to deliver our full year guidance. Press release: https://t.co… 4.2K❤ 22🔁 11 #NVSQ126 Novartis social media posts on Q1 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVS… 2.5K❤ 5🔁 3

On Tuesday, April 28, Novartis will announce its Q1 2026 results. Register to listen here: https://t.co/sqIHE3oefG #NovartisNews $NVS $NOVN #NVSQ126 2.4K❤ 12🔁 6

▶ #Investors: Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025 Press release: https://t.co/LsQDK889sL IR Webcast: https://t.co/2ZdKCI1G2z #NVSQ425 5.8K❤ 22🔁 11 #NVSQ425 Novartis social media posts on Q4 and Full-Year 2025 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more info… 4.3K❤ 10🔁 6

On Wednesday, February 4 Novartis will announce its Q4 and Full-Year 2025 results. Register to listen here: https://t.co/bxRt36UFYK #NovartisNews $NVS $NOVN #NVSQ425 3.2K❤ 11

▶ In Q3 2025, Novartis delivered solid sales and core operating income growth with strong pipeline progress. Our key growth drivers performed well, and we had important innovation milestone achievements including an FDA approval and positi… 4K❤ 12🔁 11

On Tuesday, October 28 Novartis will announce its Q3 2025 earnings. Register to listen here: https://t.co/yLwsGTAjkB #NovartisNews $NVS $NOVN #NVSQ32025 3.4K❤ 11🔁 1

▶ This #WorldHeartDay, we’re celebrating The FIT Stop event in Madrid. Inspired by the analogy of a car’s engine & the human heart, we invited citizens to partake in fun and educational activities to encourage awareness of cardiovascula… 3.4K❤ 15🔁 4

💡 Facts

🗓️Joined X in 2008 — 17 years ago.

👁️Averages 3.4K views per post.

📤Posts about 0.3× per week.

💬0.01% engagement rate.

🏅Earned the 100K Followers for passing 100K followers.

🕵️ Fake follower check

Estimated

37/100

Low Credibility score

66%

Mixed Real audience

Medium Fake-follower risk

High Data confidence

Est. 66% real, active audience · Medium fake-follower risk.
Low engagement (~1.2% of followers engage each post) — a sign of an inflated or inactive audience.
Organic base — far more followers than accounts it follows.
Established account (17+ years old).
0.01% engagement — below the ~14.4% typical for this size.

Heuristic estimate from engagement, follower ratios, account age & growth — a screening signal, not a guarantee.

About

An innovative medicines company working to reimagine medicine. See our community guidelines: http://go.novartis.social/4bqbjuA

📸 Gallery

🔀 Audience overlap

Estimated

Estimated shared audience with similar creators — useful for avoiding overlap (or doubling down) when planning a campaign.

20th Century Studios FR 18%

Saudi Green Initiative 17%

Hyundai USA 16%

UN Peacekeeping 14%

IndiaToday 14%

Ed Markey 12%

More like this

Saudi Green Initiative

20th Century Studios FR

Frequently asked questions

How much does Novartis charge for a sponsorship?

Novartis hasn't published fixed prices yet. Send a proposal through SocialDB and agree terms directly — your payment is held in escrow until the work is approved.

How do I contact Novartis for a brand deal or collaboration?

Send a paid deal or collab request right here on SocialDB — we notify Novartis, and once they accept, your payment is held safely in escrow and released when the work is approved. You don't need to track down an email.

How many followers does Novartis have?

Novartis has 287,164 followers on X.

Auto-generated from X's public data — no affiliation with or endorsement by SocialDB. Is this you? Claim it · Remove